A Safety and Performance Study of the Use of EmboBio for the Intra-arterial Treatment of Abdominopelvic Bleeding

Inclusion Criteria: * Age ≥18 years * Patient presenting with an arterial abdominopelvic bleeding or risk of bleeding requiring embolization with a permanent embolic agent, i.e. abdominal solid organs hemorrhage including angiomyolipoma, visceral aneurysms and pseudoaneurysms actively bleeding or at risk of bleeding (upper or lower gastrointestinal arteries), pelvic hemorrhage, postpartum hemorrhage in case of active leakage visualized by contrast media extravasation, soft tissue hemorrhage * Patient having provided a written informed consent Exclusion Criteria: * Known hypersensitivity to Agar-Agar * Known hypersensitivity to iodinated contrast media * Patient unable or unwilling to provide a written informed consent * Patient unable to provide informed consent due to his clinical condition * Patient participating in another interventional study * Patient implanted with Embobio device at a previous operating time * Vulnerable, pregnant, and breastfeeding population * Patient unwilling or unable to follow the study schedule * Patients unable to receive prior information on the clinical investigation due to the urgency of the situation * Target arteries diameter \> 2 mm * Vascular anatomy preventing proper placement of the catheter. * Arteriovenous shunts with a high flow rate or a diameter greater than 2 mm